FI91083B - Förfarande för expression av gener i jäst, och DNA-sekvenser samt plasmider innehållande dessa DNA-sekvenser för användning vid förfarandet - Google Patents
Förfarande för expression av gener i jäst, och DNA-sekvenser samt plasmider innehållande dessa DNA-sekvenser för användning vid förfarandet Download PDFInfo
- Publication number
- FI91083B FI91083B FI864301A FI864301A FI91083B FI 91083 B FI91083 B FI 91083B FI 864301 A FI864301 A FI 864301A FI 864301 A FI864301 A FI 864301A FI 91083 B FI91083 B FI 91083B
- Authority
- FI
- Finland
- Prior art keywords
- sequence
- gene
- dna sequence
- dna
- home
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 78
- 239000013612 plasmid Substances 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims abstract description 53
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 38
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims description 73
- 108020004414 DNA Proteins 0.000 claims abstract description 17
- 230000001124 posttranscriptional effect Effects 0.000 claims abstract description 12
- 230000001105 regulatory effect Effects 0.000 claims abstract description 12
- 230000001965 increasing effect Effects 0.000 claims abstract description 11
- 239000002243 precursor Substances 0.000 claims abstract description 10
- 210000005253 yeast cell Anatomy 0.000 claims abstract description 9
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 8
- 239000001963 growth medium Substances 0.000 claims abstract 4
- 238000012258 culturing Methods 0.000 claims abstract 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims description 25
- 244000068988 Glycine max Species 0.000 claims description 20
- 235000010469 Glycine max Nutrition 0.000 claims description 20
- 230000003834 intracellular effect Effects 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 241000196324 Embryophyta Species 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 101150055766 cat gene Proteins 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 7
- VAJVGAQAYOAJQI-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-3,8,13,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C(C=C2C(C)=CC(N2)=CC=2C(=C(CCC(O)=O)C(=C3)N=2)C)=CC(C)=C1C=C1C(C)=C(CCC(O)=O)C3=N1 VAJVGAQAYOAJQI-UHFFFAOYSA-N 0.000 claims description 5
- 108010025815 Kanamycin Kinase Proteins 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 108020005029 5' Flanking Region Proteins 0.000 claims 12
- 108010054147 Hemoglobins Proteins 0.000 claims 6
- 235000015895 biscuits Nutrition 0.000 claims 3
- 102000001554 Hemoglobins Human genes 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 101150062179 II gene Proteins 0.000 claims 1
- 108020005120 Plant DNA Proteins 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 150000003278 haem Chemical class 0.000 abstract description 31
- 230000014509 gene expression Effects 0.000 abstract description 23
- 210000004027 cell Anatomy 0.000 abstract description 22
- 230000014616 translation Effects 0.000 abstract description 14
- 230000037149 energy metabolism Effects 0.000 abstract description 6
- 238000001243 protein synthesis Methods 0.000 abstract description 6
- 239000012634 fragment Substances 0.000 abstract description 5
- 230000002068 genetic effect Effects 0.000 abstract description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 32
- 230000000694 effects Effects 0.000 description 27
- 108010063653 Leghemoglobin Proteins 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 13
- 230000033228 biological regulation Effects 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 10
- 230000002103 transcriptional effect Effects 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 238000010276 construction Methods 0.000 description 7
- 108091081024 Start codon Proteins 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000008844 regulatory mechanism Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000014493 regulation of gene expression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 108010092809 exonuclease Bal 31 Proteins 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940025294 hemin Drugs 0.000 description 2
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 150000002972 pentoses Chemical group 0.000 description 2
- 229950003776 protoporphyrin Drugs 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- 108010052384 5-Aminolevulinate Synthetase Proteins 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- DKVRNHPCAOHRSI-KQYNXXCUSA-N 7-methyl-GTP Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O DKVRNHPCAOHRSI-KQYNXXCUSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 101000643378 Homo sapiens Serine racemase Proteins 0.000 description 1
- 101150108219 ILV1 gene Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 241000589157 Rhizobiales Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100035717 Serine racemase Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000011681 asexual reproduction Effects 0.000 description 1
- 238000013465 asexual reproduction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000007859 posttranscriptional regulation of gene expression Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Enzymes And Modification Thereof (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Claims (20)
1. Förfarande för uttryckning av gener i jäst genom in-föring i jästcellen av en rekombinat-DNA-sekvens innehällan-de bäde genen som skall uttryckas och 5'-flankerande regio-nen innefattande promotorsekvensen, och odling av de trans-formerade jästcellerna i ett eget tillväxtmedium, kanneteck-nat av att man använder en 5'-flankerande region frän växt-leghemoglobin omfattande en första DNA-sekvens innehällande en promotorsekvens och en andra DNA-sekvens innehällande en signalsekvens, som regleras pä post-transkriptionsnivä av hem, hemanaloger eller hemprekursorer, och att den intracel-lulära koncentrationen av hem ökar, och att tili tillväxtme-diet tillsätts sädana kolkällor, som förorsakar en ökad int-racellulär koncentration av hem.
2. Förfarande enligt patentkravet 1, kannetecknat av att säsom en första DNA-sekvens används en frän en bakterie iso-lerad DNA-sekvens eller en frän växt-DNA in vitro syntetise-rad DNA innehällande en promotorsekvens för kombination med den andra DNA-sekvensen.
3. Förfarande enligt patentkravet 1, kannetecknat av att säsom en andra DNA-sekvens används en frän en bakterie iso-lerad DNA-sekvens eller en frän växt-DNA in vitro syntetise- li 91083 33 rad DNA innehällande en signalsekvens för kombination med den första DNA-sekvensen.
4. Förfarande enligt patentkravet 1, kännetecknat av att kolkällan väljs bland glycerol, succinat och etanol.
5. Förfarande enligt patentkravet 1, kännetecknat av att den intracellulära koncentrationen av hem ökas genom till-sats till tlilväxtmediet av ett eller flera ämnen valda ur den grupp som utgöres av hem, hemanaloger och hemprekurso-rer.
6. Förfarande enligt patentkravet 5, kännetecknat av att säsom hemanalog används föreningen deuteroporfyrin IX och/-eller säsom hemprekursor används föreningen δ-aminolevulin-syra.
7. Förfarande enligt patentkravet 1, kännetecknat av an-vändning av en DNA-sekvens som är identisk med 5'-flankeran-de regioner i sojabönleghemoglobin-gener.
8. Förfarande enligt patentkravet 7, kännetecknat av att den 5'-flankerande regionen är identisk med 5'- flankerande regioner i Lba-genen med sekvensen: GAGATACATT ATAATAATCT CTCTAGTGTC TATTTATTAT TTTATCTGGT GATATATACC TTCTCGTATA CTGTTATTTT TTCAATCTTG TAGATTTACT TCTTTTATTT TTATAAAAAA GACTTTATTT TTTTAAAAAA AATAAAGTGA ATTTTGAAAA CATGCTCTTT GACAATTTTC TGTTTCCTTT TTCATCATTG GGTTAAATCT CATAGTGCCT CTATTCAATA ATTTGGGCTC AATTTAATTA GTAGAGTCTA CATAAAATTT ACCTTAATAG TAGAGAATAG AGAGTCTTGG AAAGTTGGTT TTTCTCGAGG AAGAAAGGAA ATGTTAAAAA CTGTGATATT TTTTTTTTGG ATTAATAGTT ATGTTTATAT GAAAACTGAA AATAAATAAA CTAACCATAT TAAATTTAGA ACAACACTTC AATTATTTTT TTAATTTGAT TAATTAAAAA ATTATTTGAT TAAATTTTTT AAAAGATCGT TGTTTCTTCT TCATCATGCT GATTGACACC CTCCACAAGC CAAGAGAAAC ACATAAGCTT TGGTTTTCTC ACTCTCCAAG CCCTCTATAT AAACAAATAT TGGAGTGAAG TTGTTGCATA ACTTGCATCG AACAATTAAT AGAAATAACA GAAAATTAAA AAAGAAATAT G.
9. Förfarande enligt patentkravet 7, kännetecknat av att den 5flankerande regionen är identisk med 5flankerande regioner i Lbcl-genen med sekvensen: 34 TTCTCTTAAT ACAATGGAGT TTTTGTTGAA CATACATACA TTTAAAAAAA AATCTCTAGT GTCTATTTAC CCGGTGAGAA GCCTTCTCGT GTTTTACACA CTTTAATATT ATTATATCCT CAACCCCACA AAAAAGAATA CTGTTATATC TTTCCAAACC TGTAGATTTA TTTATTTATT TATTTATTTT TACAAAGGAG ACTTCAGAAA AGTAATTACA TAAAGATAGT GAACATCATT TTATTTATTA TAATAAACTT TAAAATCAAA CTTTTTTATA TTTTTTGTTA CCCTTTTCAT TATTGGGTGA AATCTCATAG TGAAGCCATT AAATAATTTG GGCTCAAGTT TTATTAGTAA AGTCTGCATG AAATTTAACT TAACAATAGA GAGAGTTTTC GAAAGGGAGC GAATGTTAAA AAGTGTGATA TTATATTTTA TTTCGATTAA TAATTATGTT TACATGAAAA CATACAAAAA AATACTTTTA AATTCAGAAT AATACTTAAA ATATTTATTT GCTTAATTGA TTAACTGAAA ATTATTTGAT TAGGATTTTG AAAAGATCAT TGGCTCTTCG TCATGCCGAT TGACACCCTC CACAAGCCAA GAGAAACTTA AGTTGTAAAC TTTCTCACTC CAAGCCTTCT ATATAAACAT GTATTGGATG TGAAGTTATT GCATAACTTG CATTGAACAA TAGAAAATAA CAAAAAAAAG TAAAAAAGTA GAAAAGAAAT ATG.
10. Förfarande enligt patentkravet 7, kännetecknat av att den 5'-flankerande regionen är identisk med 5'-flankerande regioner i Lbc2-genen med sekvensen: TCGAGTTTTT ACTGAACATA CATTTATTAA AAAAAACTCT CTAGTGTCCA TTTATTCGGC GAGAAGCCTT CTCGTGCTTT ACACACTTTA ATATTATTAT ATCCCCACCC CCACCAAAAA AAAAAAAACT GTTATATCTT TCCAGTACAT TTATTTCTTA TTTTTACAAA GGAAACTTCA CGAAAGTAAT TACAAAAAAG ATAGTGAACA TCATTTTTTT AGTTAAGATG AATTTTAAAA TCACACTTTT TTATATTTTT TTGTTACCCT TTTCATTATT GGGTGAAATC TCATAGTGAA ACTATTAAAT AGTTTGGGCT CAAGTTTTAT TAGTAAAGTC TGCATGAAAT TTAACTTAAT AATAGAGAGA GTTTTGGAAA GGTAACGAAT GTTAGAAAGT GTGATATTAT TATAGTTTTA TTTAGATTAA TAATTATGTT TACATGAAAA TTGACAATTT ATTTTTAAAA TTCAGAGTAA TACTTAAATT ACTTATTTAC TTTAAGATTT TGAAAAGATC ATTTGGCTCT TCATCATGCC GATTGACACC CTCCACAAGC CAAGAGAAAC TTAAGTTGTA ATTTTTCTAA CTCCAAGCCT TCTATATAAA CACGTATTGG ATGTGAAGTT GTTGCATAAC TTGCATTGAA CAATAGAAAT AACAACAAAG AAAATAAGTG AAAAAAGAAA TATG.
11. Förfarande enligt patentkravet 7, kännetecknat av att den 51 -flankerande regionen är identisk med 51 -flankerande regioner i Lbc3-genen med sekvensen: li 91083 35 TATGAAGATT AAAAAATACA CTCATATATA TGCCATAAGA ACCAACAAAA GTACTATTTA AGAAAAGAAA AAAAAAACCT GCTACATAAT TTCCAATCTT GTAGATTTAT TTCTTTTATT TTTATAAAGG AGAGTTAAAA AAATTACAAA ATAAAAATAG TGAACATCGT CTAAGCATTT TTATATAAGA TGAATTTTAA AAATATAATT TTTTTGTCTA AATCGTATGT ATCTTGTCTT AGAGCCATTT TTCTTTAAAT TGGATAAGAT CACACTATAA AGTTCTTCCT CCGAGTTTGA TATAAAAAAA ATTGTTTCCC TTTTGATTAT TGGATAAAAT CTCGTAGTGA CATTATATTA AAAAAATTAG GGCTCAATTT TTATTAGTAT AGTTTGCATA AATTTTAACT TAAAAATAGA GAAAATCTGG AAAAGGGACT GTTAAAAAGT GTGATATTAG AAATTTGTCG GATATATTAA TATTTTATTT TATATGGAAA CTAAAAAAAT ATATATTAAA ATTTTAAATT CAGAATAATA CTTAAATTAT TTATTTACTG AAAATGAGTT GATTTAAGTT TTTGAAAAGA TGATTGTCTC TTCACCATAC CAATTGATCA CCCTCCTCCA ACAAGCCAAG AGAGACATAA GTTTTATTAG TTATTCTGAT CACTCTTCAA GCCTTCTATA TAAATAAGTA TTGGATGTGA AGTTGTTGCA TAACTTGCAT TGAACAATTA ATAGAAATAA CAGAAAAGTA GAAAAGAAAT ATG.
12. DNA-sekvens, som kan användas i rekombinant-DNA-segment vid genomförandet av förfarandet enligt kraven 1-11, känne-tecknad av att den innefattar en första DNA-sekvens innehal-lande en promotorsekvens, och en andra DNA-sekvens innehäl-lande en signalsekvens, som regleras pä post-transkriptions-nivä av hem, hemanaloger eller hemprekursorer, och som är identisk med den 5 * -flankerande regionen i vaxtleghemoglo-bin.
13. DNA-sekvens, som används vid genomförande av förfaran-det enligt patentkravet 12, käxmetecknad av att den är identisk med signalsekvensen av sojabönleghemoglobin-gener.
14. DNA-sekvens enligt patentkravet 13, kännetecknad av att den är identisk med 5'-flankerande regioner av Lba-genen med sekvensen: GAGATACATT ATAATAATCT CTCTAGTGTC TATTTATTAT TTTATCTGGT GATATATACC TTCTCGTATA CTGTTATTTT TTCAATCTTG TAGATTTACT TCTTTTATTT TTATAAAAAA GACTTTATTT TTTTAAAAAA AATAAAGTGA ATTTTGAAAA CATGCTCTTT GACAATTTTC TGTTTCCTTT TTCATCATTG GGTTAAATCT CATAGTGCCT CTATTCAATA ATTTGGGCTC AATTTAATTA GTAGAGTCTA CATAAAATTT ACCTTAATAG TAGAGAATAG AGAGTCTTGG AAAGTTGGTT TTTCTCGAGG AAGAAAGGAA ATGTTAAAAA CTGTGATATT TTTTTTTTGG ATTAATAGTT ATGTTTATAT GAAAACTGAA AATAAATAAA CTAACCATAT TAAATTTAGA ACAACACTTC AATTATTTTT TTAATTTGAT TAATTAAAAA ATTATTTGAT TAAATTTTTT AAAAGATCGT TGTTTCTTCT TCATCATGCT GATTGACACC CTCCACAAGC CAAGAGAAAC ACATAAGCTT TGGTTTTCTC ACTCTCCAAG CCCTCTATAT AAACAAATAT TGGAGTGAAG TTGTTGCATA ACTTGCATCG AACAATTAAT AGAAATAACA GAAAATTAAA AAAGAAATAT G. 36
15. DNA-sekvens enligt patentkravet 13, kännetecknad av att den är identisk med 51 - flankerande regioner av Lbcl-genen med sekvensen: TTCTCTTAAT ACAATGGAGT TTTTGTTGAA CATACATACA TTTAAAAAAA AATCTCTAGT GTCTATTTAC CCGGTGAGAA GCCTTCTCGT GTTTTACACA CTTTAATATT ATTATATCCT CAACCCCACA AAAAAGAATA CTGTTATATC TTTCCAAACC TGTAGATTTA TTTATTTATT TATTTATTTT TACAAAGGAG ACTTCAGAAA AGTAATTACA TAAAGATAGT GAACATCATT TTATTTATTA TAATAAACTT TAAAATCAAA CTTTTTTATA TTTTTTGTTA CCCTTTTCAT TATTGGGTGA AATCTCATAG TGAAGCCATT AAATAATTTG GGCTCAAGTT TTATTAGTAA AGTCTGCATG AAATTTAACT TAACAATAGA GAGAGTTTTC GAAAGGGAGC GAATGTTAAA AAGTGTGATA TTATATTTTA TTTCGATTAA TAATTATGTT TACATGAAAA CATACAAAAA AATACTTTTA AATTCAGAAT AATACTTAAA ATATTTÄTTT GCTTAATTGA TTAACTGAAA ATTATTTGAT TAGGATTTTG AAAAGATCAT TGGCTCTTCG TCATGCCGAT TGACACCCTC CACAAGCCAA GAGAAACTTA AGTTGTAAAC TTTCTCACTC CAAGCCTTCT ATATAAACAT GTATTGGATG TGAAGTTATT GCATAACTTG CATTGAACAA TAGAAAATAA CAAAAAAAAG TAAAAAAGTA GAAAAGAAAT ATG.
16. DNA-sekvens enligt patentkravet 13, kännetecknad av att den är identisk med 5'-flankerande regioner av Lbc2-genen med sekvensen: TCGAGTTTTT ACTGAACATA CATTTATTAA AAAAAACTCT CTAGTGTCCA TTTATTCGGC GAGAAGCCTT CTCGTGCTTT ACACACTTTA ATATTATTAT ATCCCCACCC CCACCAAAAA AAAAAAAACT GTTATATCTT TCCAGTACAT TTATTTCTTA TTTTTACAAA GGAAACTTCA CGAAAGTAAT TACAAAAAAG ATAGTGAACA TCATTTTTTT AGTTAAGATG AATTTTAAAA TCACACTTTT TTATATTTTT TTGTTACCCT TTTCATTATT GGGTGAAATC TCATAGTGAA ACTATTAAAT AGTTTGGGCT CAAGTTTTAT TAGTAAAGTC TGCATGAAAT TTAACTTAAT AATAGAGAGA GTTTTGGAAA GGTAACGAAT GTTAGAAAGT GTGATATTAT TATAGTTTTA TTTAGATTAA TAATTATGTT TACATGAAAA TTGACAATTT ATTTTTAAAA TTCAGAGTAA TACTTAAATT ACTTATTTAC TTTAAGATTT TGAAAAGATC ATTTGGCTCT TCATCATGCC GATTGACACC CTCCACAAGC CAAGAGAAAC TTAAGTTGTA ATTTTTCTAA CTCCAAGCCT TCTATATAAA CACGTATTGG ATGTGAAGTT GTTGCATAAC TTGCATTGAA CAATAGAAAT AACAACAAAG AAAATAAGTG AAAAAAGAAA TATG.
17. DNA-sekvens enligt patentkravet 13, kännetecknad av att den är identisk med 5'-flankerande regioner av Lbc3-genen med sekvensen: II 91083 37 TATGAAGATT AAAAAATACA CTCATATATA TGCCATAAGA ACCAACAAAA GTACTATTTA AGAAAAGAAA AAAAAAACCT GCTACATAAT TTCCAATCTT GTAGATTTAT TTCTTTTATT TTTATAAAGG AGAGTTAAAA AAATTACAAA ATAAAAATAG TGAACATCGT CTAAGCATTT TTATATAAGA TGAATTTTAA AAATATAATT TTTTTGTCTA AATCGTATGT ATCTTGTCTT AGAGCCATTT TTGTTTAAAT TGGATAAGAT CACACTATAA AGTTCTTCCT CCGAGTTTGA TATAAAAAAA ATTGTTTCCC TTTTGATTAT TGGATAAAAT CTCGTAGTGA CATTATATTA AAAAAATTAG GGCTCAATTT TTATTAGTAT AGTTTGCATA AATTTTAACT TAAAAATAGA GAAAATCTGG AAAAGGGACT GTTAAAAAGT GTGATATTAG AAATTTGTCG GATATATTAA TATTTTATTT TATATGGAAA CTAAAAAAAT ATATATTAAA ATTTTAAATT CAGAATAATA CTTAAATTAT TTATTTACTG AAAATGAGTT GATTTAAGTT TTTGAAAAGA TGATTG7CTC TTCACCATAC CAATTGATCA CCCTCCTCCA ACAAGCCAAG AGAGACATAA GTTTTATTAG TTATTCTGAT CACTCTTCAA GCCTTCTATA TAAATAAGTA TTGGATGTGA AGTTGTTGCA TAACTTGCAT TGAACAATTA ATAGAAATAA CAGAAAAGTA GAAAAGAAAT ATG.
18. Rekombinant-DNA-sekvens, som kan användas i forfarandet enligt patentkraven 1-12, käxmetecknad av att den innehaller den gen, som önskas uttryckas samt DNA-sekvensen enligt vil-ken som heist av patentkraven 12-17.
19. Plasmid som kan användas vid forfarandet enligt patent-kravet 1 för framställning av kloramfenikol-acetyl-transfe-ras (CAT), kannetecknad av att den har designerats YEP Lb CAT och utan CAT-genen innehäller en promotorsekvens och signalsekvens i en DNA-sekvens, som innehaller den 5'-flan-kerande regionen av sojabönleghemoglobin-genen Lbc3 och vars struktur har presenterats i schemat 6.
20. Plasmid som kan användas vid förfarandet enligt patent-kravet 1 för framställning av neomycinfosfotransferas (NPT) II, käxmetecknad av att den har designerats YEP 5 Lb Km och utan NPT II-genen innehäller en promotorsekvens och signalsekvens i en DNA-sekvens, som innehäller den 5'-flankerande regionen av sojabönleghemoglobin-genen Lbc3 och vars struktur har presenterats i schemat 8.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK488985A DK162900C (da) | 1985-10-24 | 1985-10-24 | Fremgangsmaade til ekspression af gener i gaer samt dna-fragment, rekombineret dna-segment og plasmider, hvor disse indgaar til brug ved udoevelse af fremgangsmaaden |
| DK488985 | 1985-10-24 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI864301A0 FI864301A0 (sv) | 1986-10-23 |
| FI864301A7 FI864301A7 (sv) | 1987-04-25 |
| FI91083B true FI91083B (sv) | 1994-01-31 |
| FI91083C FI91083C (sv) | 1994-05-10 |
Family
ID=8137569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI864301A FI91083C (sv) | 1985-10-24 | 1986-10-23 | Förfarande för expression av gener i jäst, och DNA-sekvenser samt plasmider innehållande dessa DNA-sekvenser för användning vid förfarandet |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4849348A (sv) |
| EP (1) | EP0220679B1 (sv) |
| JP (1) | JPS62181787A (sv) |
| AT (2) | AT396249B (sv) |
| AU (1) | AU593296B2 (sv) |
| BR (1) | BR8605221A (sv) |
| CA (1) | CA1333162C (sv) |
| DE (2) | DE3688549T2 (sv) |
| DK (1) | DK162900C (sv) |
| ES (1) | ES2054608T3 (sv) |
| FI (1) | FI91083C (sv) |
| FR (1) | FR2598432B1 (sv) |
| GB (1) | GB2183656B (sv) |
| IE (1) | IE59114B1 (sv) |
| NL (1) | NL8602657A (sv) |
| NO (1) | NO175103C (sv) |
| NZ (1) | NZ217948A (sv) |
| PT (1) | PT83616B (sv) |
| SE (1) | SE8604517L (sv) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK162399C (da) * | 1986-01-28 | 1992-03-23 | Danisco | Fremgangsmaade til ekspression af gener i baelgplanteceller, dna-fragment, rekombineret dna-fragment samt plasmid til brug ved udoevelsen af fremgangsmaaden |
| WO1994027428A1 (en) * | 1993-05-24 | 1994-12-08 | University Of Massachusetts Medical Center | Post-transcriptional gene regulation by trace minerals |
| US5824511A (en) * | 1995-08-01 | 1998-10-20 | University Technology Corporation | Method for enhancing the production of hemoproteins |
| US6575703B2 (en) | 2001-07-20 | 2003-06-10 | General Electric Company | Turbine disk side plate |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341302C (en) * | 1983-02-22 | 2001-10-09 | Rae Lyn Burke | Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein |
-
1985
- 1985-10-24 DK DK488985A patent/DK162900C/da not_active IP Right Cessation
-
1986
- 1986-06-13 US US06/874,069 patent/US4849348A/en not_active Expired - Fee Related
- 1986-10-15 NZ NZ217948A patent/NZ217948A/xx unknown
- 1986-10-21 GB GB8625180A patent/GB2183656B/en not_active Expired - Lifetime
- 1986-10-23 DE DE8686114704T patent/DE3688549T2/de not_active Expired - Fee Related
- 1986-10-23 ES ES86114704T patent/ES2054608T3/es not_active Expired - Lifetime
- 1986-10-23 SE SE8604517A patent/SE8604517L/sv not_active Application Discontinuation
- 1986-10-23 IE IE279386A patent/IE59114B1/en not_active IP Right Cessation
- 1986-10-23 FI FI864301A patent/FI91083C/sv not_active IP Right Cessation
- 1986-10-23 AU AU64338/86A patent/AU593296B2/en not_active Ceased
- 1986-10-23 AT AT0282386A patent/AT396249B/de not_active IP Right Cessation
- 1986-10-23 AT AT86114704T patent/ATE90386T1/de active
- 1986-10-23 DE DE19863636117 patent/DE3636117A1/de not_active Ceased
- 1986-10-23 EP EP86114704A patent/EP0220679B1/en not_active Expired - Lifetime
- 1986-10-23 NL NL8602657A patent/NL8602657A/nl not_active Application Discontinuation
- 1986-10-23 NO NO864250A patent/NO175103C/no unknown
- 1986-10-24 FR FR868614807A patent/FR2598432B1/fr not_active Expired
- 1986-10-24 PT PT83616A patent/PT83616B/pt not_active IP Right Cessation
- 1986-10-24 CA CA000521391A patent/CA1333162C/en not_active Expired - Fee Related
- 1986-10-24 BR BR8605221A patent/BR8605221A/pt not_active Application Discontinuation
- 1986-10-24 JP JP61253530A patent/JPS62181787A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK173186B1 (da) | Gærpromotor, vektor indeholdende en sådan promotor, gær transformeret med en sådan vektor og fremgangsmåde til fremstilling | |
| US4914027A (en) | Process for the microbiological preparation of human serum albumin | |
| AU599072B2 (en) | A method for the expression of genes in plants, parts of plants, and plant cell cultures, and DNA fragments, plasmids and transformed microorganisms to be used when carrying out the method, as well as the use thereof for the expression of genes in plants, parts of plants, and plant cell cultures | |
| JP2837407B2 (ja) | 生物学的に活性なｐｄｇｆ類似因子の真核生物細胞内での発現 | |
| US5436393A (en) | Potato tuber specific transcriptional regulation | |
| JPH07503137A (ja) | 血清ヒトアルブミン，製剤及び利用 | |
| EP0118393B1 (en) | Methods and compositions for expression of competent eukaryotic gene products | |
| Tabuchi et al. | Genetic organization and nucleotide sequence of the stability locus of IncFII plasmid NR1 | |
| FI91083B (sv) | Förfarande för expression av gener i jäst, och DNA-sekvenser samt plasmider innehållande dessa DNA-sekvenser för användning vid förfarandet | |
| WO1987003619A1 (en) | PROCESS FOR ENHANCING TRANSLATIONAL EFFICIENCY OF EUKARYOTIC mRNA | |
| US5104795A (en) | Shortened phosphoglycerate kinase promoter | |
| WO1987005935A1 (en) | Methods and compositions for expression of competent eukaryotic gene products | |
| KR920007685B1 (ko) | 발현벡터와 그의 제조방법 | |
| AU621277B2 (en) | Shortened phosphoglycerate kinase promoter | |
| US5646010A (en) | Methods and compositions for expression of competent eukaryotic gene products | |
| Katsuya et al. | Construction of a new plasmid vector that can express cloned cDNA in all translational reading frames | |
| WO1990009434A1 (en) | Production of superoxide dismutase in pichia pastoris yeast cells | |
| HU213418B (en) | Process for producing polypeptides using bacterial host cells containing expression plasmids with deo promoter | |
| CN119841932A (zh) | 一种表达iii型胶原蛋白col17a1的重组工程菌的制备方法 | |
| KR0185980B1 (ko) | 알부민 유전자-함유 플라스미드, 이를 함유하는 형질전환체, 이러한 형질전환체의 생산방법 및 알부민의 생산방법 | |
| KR0176412B1 (ko) | 브레비박테리움 락토퍼멘텀의 글루코스 효소 ii를 코드하는 유전자 및 이의 발현 | |
| KR20060069540A (ko) | 마 모자이크바이러스 전체 게놈을 함유하는 식물발현용 벡터 | |
| WO1993003138A1 (en) | A method for over-expressing nucleic acids using an enhancer sequence from potato virus x | |
| KR19990033549A (ko) | 한세눌라 폴리모르파의 지에이피디에이치 유전자 및 이의 프로모터 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Owner name: DANISCO A/S |
|
| BB | Publication of examined application | ||
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: DANISCO A/S |